Lung AI vs Tempus ECG-Low EF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Lung AI

by Multiple (e.g., RevealDx, Optellum, LungLife AI, Qure.ai, Arterys, DeepHealth, HeartLung.AI)

Tempus ECG-Low EF

by Tempus

AI Verdict

Tool A provides real-time, AI-powered ultrasound imaging for both cardiac and lung conditions, offering visual data and detections directly on a handheld device. Tool B, conversely, is an AI software that analyzes existing 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction, integrating into existing healthcare facility workflows. While both assist in identifying cardiac risks, they utilize distinct diagnostic modalities and deployment approaches.

Choose Lung AI if…

Choose Lung AI if you require a portable, real-time imaging solution for immediate bedside assessment of lung and cardiac conditions. Its handheld ultrasound platform with integrated AI is ideal for emergency medicine or critical care settings where rapid visual diagnosis, guided image capture, and on-device processing are essential for quick decision-making.

View Lung AI →

Choose Tempus ECG-Low EF if…

Choose Tempus ECG-Low EF if your primary need is to screen and identify patients at risk of heart failure by analyzing standard 12-lead ECG recordings. This AI software is best suited for integration into existing healthcare facility workflows to leverage routine ECG data for the detection of low left ventricular ejection fraction in patients aged 40 and older.

View Tempus ECG-Low EF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Lung AI	Tempus ECG-Low EF
Deployment	Cloud-based, integrated with existing platforms (e.g., RapidAI), and potentially on-premise.	Integrates with current ECG platforms and electronic health records (EHRs).
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

Tool A emphasizes an 'easy-to-use' handheld platform with 'guided image capture' and 'AI-powered POCUS education and training (Exo U),' indicating a strong focus on user experience and skill development. Its on-device AI processing also simplifies operation by removing internet dependency, enhancing point-of-care usability.

Clinical Value

Lung AI

Tool A offers real-time, AI-powered detection for multiple critical conditions (pleural effusion, consolidation/atelectasis, cardiac conditions) directly at the point of care, enabling immediate clinical decisions. While Tool B provides valuable risk stratification for low LVEF from ECGs, Tool A's direct imaging and broader real-time diagnostic scope offer a more immediate and diverse clinical impact.

Pricing & Value

Tie

Both tools require direct contact with the vendor for pricing information, making it impossible to compare their cost-effectiveness or overall value proposition. Without transparent pricing details, a definitive winner cannot be determined in this dimension.

Enterprise Readiness

Tempus ECG-Low EF

Both tools are HIPAA compliant, have BAAs, and FDA clearance, indicating foundational enterprise readiness. However, Tool B's deployment as 'Software, integrated into healthcare facility workflows' suggests a more seamless integration into existing IT infrastructures and clinical pathways compared to Tool A's hardware-dependent, on-device deployment.

Innovation

Lung AI

Tool A is pioneering a high-performance, handheld ultrasound platform with integrated, on-device AI for real-time diagnostics, representing a significant innovation in point-of-care imaging accessibility. Its combination of advanced hardware and AI in a portable form factor is more disruptive than Tool B's application of AI to an existing diagnostic test.

Support & Docs

Lung AI

Tool A explicitly highlights 'Exo U (AI-powered POCUS education and training)' as a key feature, demonstrating a clear commitment to user enablement and ongoing learning. Tool B does not specify any equivalent support or documentation features in its description, giving Tool A an advantage in this area.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Lung AI	Tempus ECG-Low EF
Name	Lung AI	Tempus ECG-Low EF
Company	Exo	Tempus AI
Tagline	Handheld AI Ultrasound for Smarter Cardiac and Lung Scanning.	AI-Powered Precision Medicine & Genomic Testing
Primary Modality/Input	High-performance, handheld ultrasound platform	12-lead ECG recordings
Core Clinical Purpose	Empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes, particularly for cardiac and lung scanning.	Analyzes ECGs to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) to aid clinicians in further evaluation for patients at risk of heart failure.
Specific Detections/Outputs	AI-powered detection of pleural effusion, consolidation/atelectasis, automated AI-based indicators for cardiac conditions (e.g., heart failure, hypertrophy)	Binary output (Low LVEF Detected / Not Detected) for signs of low Left Ventricular Ejection Fraction (LVEF u226440%)

Videos

Demos, reviews, and walkthroughs featuring Lung AI and Tempus ECG-Low EF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a physician's existing clinical workflow, and what is their immediate clinical impact on patient evaluation?

Lung AI by Exo integrates directly with the handheld Exo Iris ultrasound device, providing real-time AI-powered detection and feedback at the point of care, even without internet connectivity. This allows for immediate assessment of cardiac and lung conditions, accelerating diagnosis and treatment pathways. Tempus ECG-Low EF is a software solution designed to integrate into existing healthcare facility workflows, analyzing 12-lead ECG recordings to provide a binary output indicating signs of low LVEF, aiding in the identification of at-risk heart failure patients for further evaluation.

What are the specific mechanisms for integrating each tool's output into the Electronic Health Record (EHR), and how does this impact data flow and documentation?

Tempus ECG-Low EF is designed to work with existing ECG platforms and EHRs, enabling advanced AI deployment and insights directly within clinical workflows, which suggests a streamlined data flow for results. For Lung AI, while it processes on-device, the broader Exo ecosystem includes 'Exo Works' software for POCUS workflow and documentation, which centralizes image storage and automates documentation, implying a pathway for EHR integration of ultrasound images and reports.

What are the reported accuracy and sensitivity metrics for each tool's AI-powered detection, and how should these be considered in clinical decision-making?

For Lung AI, clinical studies showed improved accuracy in lung ultrasound interpretation with AI assistance, with an 18% improvement in sensitivity for pleural effusion and a 16% boost in sensitivity for consolidation/atelectasis. Tempus ECG-Low EF demonstrated 86% sensitivity and 83% specificity for classifying patients with low LVEF, with a negative predictive value of 98%. Both tools are intended to aid clinicians and should be interpreted in conjunction with other diagnostic information and clinical history, not as standalone diagnostic tools.

What is the expected learning curve for physicians to effectively utilize each tool, and how quickly can a practice expect to realize clinical value from their implementation?

Exo's Lung AI, integrated with the Exo Iris handheld ultrasound, includes 'Exo U' for POCUS education and training, suggesting a learning curve for ultrasound proficiency, though the AI aims to simplify image acquisition and interpretation. Tempus ECG-Low EF analyzes existing 12-lead ECGs and provides a binary output, likely presenting a minimal learning curve for physicians in terms of operation, with clinical value realized by aiding in earlier identification of at-risk heart failure patients.

What are the key considerations for rolling out each tool across multiple clinical sites, and what kind of ongoing support is available to ensure smooth operation and adoption?

Exo's Lung AI, being on a handheld device with on-device AI processing, offers portability for multi-site deployment, and Exo provides POCUS workflow deployment and operations support. Tempus ECG-Low EF, as software integrated into healthcare facility workflows, can be deployed at scale across hospitals and outpatient settings, with Tempus focusing on partnerships with EHR providers for seamless implementation and offering multi-site study capabilities for investigational algorithms.

Beyond standard compliance, what additional security measures are in place to protect patient data, and what audit-trail features are available to track tool usage and results?

Lung AI operates with on-device AI processing, meaning it functions without an internet connection, which inherently keeps data local and potentially enhances security by reducing external data transfer risks. While specific audit-trail features for Exo are not detailed, Tempus employs EHR integrations and patient clinical data to filter eligible patients for ECG-AI use, and its systems are designed to track patients for further referral or diagnostic follow-up, implying robust data management.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Lung AI or Tempus ECG-Low EF

Backers

Who funded each tool's parent company.